Sign in
Active, not recruitingPhase 2

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Key facts

Who runs it
Sanofi
Where
Birmingham, Boston, Danbury, Denver, Gainesville, Hannibal, Hershey, Houston, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Phoenix, Portland, Sacramento, Salt Lake City, and Spartanburg, United StatesSee the 18 sitesAlso in 8 other countries, 22 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
185 people, planned
Started
20 Jun 2024
Expected to end
30 Sept 2028
Type of study
Interventional
Treatments tested
  • SAR447537
Record updated
13 April 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Males or females 18-80 years of age, inclusive, at the time of screening
  • Diagnosis of AATD
  • Evidence of emphysema secondary to AATD
  • FEV1 of ≥ 30% predicted at screening and post-bronchodilator FEV1/FVC<0.7
  • Current non-smoking status

Who cannot take part

  • Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
  • Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
  • On waiting list for lung or liver transplant
  • Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening
  • Known or suspected allergy to components of SAR447537, A1PI or human IgG
  • Active cancers or has a history of malignancy within 5 years prior to screening
  • History of unstable cor pulmonale; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
  • Uncontrolled diabetes mellitus despite adequate antidiabetic pharmacologic treatment with a screening HbA1c value ≥9%
  • For newly identified participants
  • Evidence of decompensated cirrhosis

Where in United States

Also in 8 other countries, 22 sites

  • UAB Lung Health Center- Site Number : 105Birmingham, United States
  • Brigham and Women's Hospital -75 Francis Street- Site Number : 131Boston, United States
  • Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119Danbury, United States
  • National Jewish Medical and Research Center- Site Number : 123Denver, United States
  • University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101Gainesville, United States
  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111Hannibal, United States
  • Penn State Health Milton S. Hershey Medical Center- Site Number : 122Hershey, United States
  • Houston Methodist Hospital- Site Number : 113Houston, United States
  • Indiana University- Site Number : 127Indianapolis, United States
  • David Geffen School of Medicine at UCLA- Site Number : 124Los Angeles, United States
  • University of Minnesota-420 Delaware Str SE- Site Number : 125Minneapolis, United States
  • Columbia University Irving Medical Center- Site Number : 104New York, United States
  • Temple University Hospital - 3401 N Broad St- Site Number : 130Philadelphia, United States
  • St Joseph's Hospital and Medical Center- Site Number : 126Phoenix, United States
  • Oregon Health and Science University- Site Number : 117Portland, United States
  • University of California Davis Medical Center- Site Number : 110Sacramento, United States
  • University of Utah Health Care- Site Number : 106Salt Lake City, United States
  • Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120Spartanburg, United States

About the trial

What the trial wants to find out

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

The group in the trial

  • SAR447537 (INBRX-101)Treatment being tested

    A1PI, Recombinant, Bivalent Fc Fusion Protein, in a solution for intravenous injection

    Treatment: SAR447537

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Record updated
13 April 2026